Cell potency assay for therapeutic potential

An in vitro or ex vivo method to determine the therapeutic potential of a population of cells comprising:

• a) measuring expression of a plurality of genes in a population of cells comprising hematopoietic cells;
• b) identifying increased expression in at least two of the plurality of genes in the population of cells compared to a control population of cells;
• wherein the hematopoietic cells have sufficient therapeutic potential if the increased expression in the at least two of the plurality of genes in the population of cells is at least two-fold.

(canceled)

55-56. (canceled)

63-68. (canceled)

70-73. (canceled)

75-78. (canceled)

80-105. (canceled)

(canceled)

109-112. (canceled)

114-115. (canceled)

A gene expression panel for identifying a population of hematopoietic cells having therapeutic potential, comprising a plurality of genes selected from the group consisting of:

• HEYi, COX2, ULBP2, HASI, GEMi, REN, COLIAI, ANGPTI, CXCL6, PROMI, BMP4, ANGPT2, IKBKB, PECAMI, TIEI, AREG, CASP3, JAGI, ARNT, CREM, CTGF, CD40L, BAX, HGF, SOD2, PDGFB, THBSI, DUSP4, CYR61, CXCLI, TEK, CFLAR, IGF2, CXCR4, MMP2, FGF2, PTGS2, RAC2, PDGFR, NR4A2, NR4A3, TERT, TGFBI, MMP9, CD40, CD44, HMGBI, NOS3, KDR, ITGBI, CTNNBI, CSF3, IL8, PLAUR, BCL2, BMP2, CSFI, AKTI, VEGFA, ICAMI, CXCL3, CASP8, CD34, IL1A, CD47, CCL7, HIFIA, EDNI, SIPRI, CCRI, SMAD4, FLTI, CD151, PGF, NFKBI, SMAD2, CXCR7, TGFB3, CXCL5, CCNDI, HBEGF, NR3C1, TNF, ITGAL, CXCR2, STATI, ITGA4, LIF, RASAI, CDH5, EFNB2, RGS16, CXCL2, ITGA5, CXCL12, TIMPI, FOSL2, ITGB2, and TIMP2.

119-123. (canceled)